The Dose of Sugammadex for Rapid Reversal of Profound Neuromuscular Block in Young and Elderly Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01890057

Enrollment

Registered

2013-07-01

Start date

2013-06-30

Completion date

2014-01-31

Last updated

2014-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia Recovery Period, Neuromuscular Blockade

Brief summary

To find out the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound rocuronium-induced neuromuscular block in young and elderly adult patients.

Detailed description

A previous study reported that elderly patients required a longer time to recover from rocuronium induced neuromuscular block compared to younger patients. Therefore, the aim of this study is to find out the dose of sugammadex for rapid recovery from profound neuromuscular block in young and elderly adult patients.

Interventions

DRUGSugammadex

The dose of sugammadex

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* 20-40 years or ≥70 years ASA class I-II patients who received surgery less than 2 hours.

Exclusion criteria

* anticipated difficult intubation * neuromuscular, hepatic or renal disorders * drug allergy * body mass index \>30 kg/m2 or body mass index \<18 kg/m2 * emergency surgery

Design outcomes

Primary

Measure	Time frame
The dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block	2 hour

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026